Bioinduction

Bioinduction Ltd. is a UK-based medical technology company founded in 2002, specializing in advanced neuromodulation devices for neurological disorders, particularly Parkinson’s disease. The company develops innovative implantable neurostimulation systems aimed at enhancing patient outcomes and surgical efficiency. Their flagship product, the Picostim DyNeuMo platform, is an ultra-compact device designed for deep brain stimulation and other neurostimulation therapies. This technology simplifies the surgical process, reducing operation time by approximately 40% and improving patient safety and comfort. Bioinduction also focuses on developing intelligent, adaptive neuromodulation therapies that respond dynamically to patient needs. With a commitment to innovation, Bioinduction serves healthcare providers, neurosurgeons, and medical institutions. The company is ISO 13485 certified, ensuring compliance with quality management standards for medical devices. In 2023, Bioinduction was acquired by Amber Therapeutics, further expanding its reach in the development of intelligent closed-loop neuromodulation therapies.

• Employees 3
• Founded 2002